BiomX · raw details

BiomX is a clinical-stage microbiome company developing both natural and engineered phage cocktails designed to target and destroy bacteria in the treatment of chronic diseases, such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. BiomX discovers and validates proprietary bacterial targets and customizes phage compositions against these targets.

The company's platforms use computational and synthetic biology and research from Doctors Rotem Sorek, Eran Elinav, and Eran Segal of the Weizmann Institute of Science and Doctor Timothy K. Lu of the Massachusetts Institute of Technology.

With the establishment of X Security & Defense, BiomX intends to expand its presence in security and defense markets by identifying and commercializing technologies that address evolving operational needs across national security, emergency response, and critical infrastructure protection.